The statin era in cardiovascular medicine: What's next?

Cardiovascular Reviews and Reports

Volumn 22, Issue 11, 2001, Pages 639-648

  Shepherd, J ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATINE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; ISCHEMIC HEART DISEASE; PATIENT COMPLIANCE; REVIEW;

EID: 0034759586     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. The underused miracle drugs: The statin drugs are to atherosclerosis what penicillin was to infectious disease
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
7. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
8. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
9. Drug treatment of lipid disorders
10. Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,662 men
11. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial
12. Aggressive lipid-lowering therapy: A clinical imperative
13. Summary of the second report of the National Cholesterol Education Program [NCEP] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
14. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
15. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia
16. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormalities in men with premature coronary artery disease
17. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
18. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome
19. Primary prevention of coronary heart disease: Role of cholesterol control in the United States
20. Statin + fibrate combination therapy: Fluvastatin with bezafibrate or ciprofibrate in high-risk patients with vascular disease
21. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels
22. Efficacy and safety of cerivastatin/bezafibrate and cerivastatin/fenofibrate combination therapies
23. Niacin plus simvastatin, but not antioxidant vitamins, protect against atherosclerosis and clinical events in CAD patients with low HDLC
24. Cohort study of 132 patients on statin-niacin combination therapy for dyslipidemia
25. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia
26. Combination drug therapy for combined hyperlipidemia
27. Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: A prospective trial
28. Lp(a) lipoprotein - An independent risk factor for coronary heart disease after menopause
29. Lipoprotein(a) as a predictor of myocardial infarction in middle-aged men
30. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease
31. Hormone replacement therapy and ischaemic heart disease among postmenopausal women
32. The effect of nicotinic acid therapy on plasma high-density lipoprotein subfraction distribution and composition and on apolipoprotein A-I metabolism
33. Treatment of hyperlipidemia with combined niacin-statin regimens
34. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy
35. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil
36. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals
37. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
38. Statins do more than just lower cholesterol
39. Are there potential non-lipid-lowering uses of statins?
40. Pravastatin inhibits cellular cholesterol synthesis and increases low-density lipoprotein receptor activity in macrophages: In vitro and in vivo studies
41. Effect of pravastatin on outcomes after cardiac transplantation
42. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease
43. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results
44. International comparison of awareness and attitudes towards coronary risk factor reduction: The HELP Study
45. Management of high blood cholesterol by primary care physicians: Diffusion of the National Cholesterol Education Program Adult Treatment Panel Guidelines
46. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines
47. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity
48. Association of coronary heart disease risk factors with microscopic qualities of coronary atherosclerosis in youth
49. Cardiovascular disease risk factor variables at the preschool age: The Bogalusa Heart Study
50. The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
51. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
52. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS: West of Scotland Coronary Prevention Study
53. Cost effectiveness of treating hyperlipidemia in the presence of diabetes: Who should be treated?